A Phase 3 interventional study of Eltrombopag and Azacitidine in Thrombocytopaenia, sponsored by Novartis Pharmaceuticals. Terminated at 158 sites in 30 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-12-12.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 53 studies testing eltrombopag in Thrombocytopenia — 2 open to participants now, 3 under way, none of them phase 3. eltrombopag · Thrombocytopenia.
Among the 53 studies testing eltrombopag in Thrombocytopenia, this one has the largest enrollment, is one of 4 that started in 2014, is one of 9 in phase 3, and was the 43rd registered.
484 studies on the registry are indexed under Thrombocytopenia; 102 are open to participants now.
Browse Thrombocytopenia studies →2 of the 53 studies testing eltrombopag in Thrombocytopenia are open now, in 2 countries. Recruiting first, the newest first:
Institute of Hematology & Blood Diseases Hospital, China · Sites in China
Ages 18+
National Heart, Lung, and Blood Institute (NHLBI) · Sites in United States
Ages 3–99
By country, each count listing its studies:
eltrombopag: first FDA approval 2008 (PROMACTA), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →
Of the 66 Thrombocytopenia studies recruiting now, 44 (67%) set no upper age limit and 18 (27%) stop at 75 or younger; 10 take children under 18; 3 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
53 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 33 · Phase 3 13 · Phase 4 3
First in 2005; this study’s year is marked. 4 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 356 is above the median of 54 across 336 interventional studies indexed under Thrombocytopenia.
Median enrollment 40 across the 53 interventional studies. Of the 45 that completed or were terminated, 25 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
22 of 53 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
10 studies in Thrombocytopenia by Novartis: none open now, none under way, none of them phase 3. Of 8 finished, 6 (75%) have results posted.
Among the 10 studies in Thrombocytopenia by Novartis, this one is one of 2 that started in 2014, is one of 3 in phase 3, and was the 9th registered.
Novartis’s Thrombocytopenia studies by the year they started, since 2003.
None of the studies under way reaches primary completion within a year.
Among the 53 studies testing eltrombopag in Thrombocytopenia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novartis’s 10 in Thrombocytopenia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Eltrombopag olamine (SB-497115-GR) is an orally bioavailable, small molecule thrombopoietin receptor agonist that may be beneficial in medical disorders associated with thrombocytopenia. Eltrombopag has been shown to increase platelet counts in patients with thrombocytopenia from various etiologies (Idiopathic thrombocytopenic purpura [ITP], liver disease, aplastic anemia and chemotherapy induced thrombocytopenia). Approximately 350 subjects will be randomized in a 1:1 ratio (175 into the eltrombopag arm and 175 into the placebo arm). Approximately 55 subjects will be enrolled into the azacitidine. Subjects with intermediate-1, intermediate-2 or high risk MDS by IPSS, and baseline platelet count of \<75 Giga (10\^9) per liter (Gi/L) will only be enrolled. This is a randomized, double-blind, parallel group, placebo-controlled study designed to explore the platelet supportive care effects of eltrombopag versus placebo in combination with the standard of care hypomethylating agent, azacitidine. The primary objective of this study is to determine the effect of eltrombopag versus placebo on the proportion of subjects who are platelet transfusion free during the first 4 cycles of azacitidine therapy. Key secondary endpoints include overall survival, disease response, and disease progression.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Eligible subject will receive a starting dose of eltrombopag of 200 milligrams (mg) (100 mg for subjects of East Asian heritage). Dose modifications of eltrombopag will be permitted by 100 mg increments (50 mg increments for East Asians) to a lowest dose of 100 mg (50 mg for East Asian heritage) or a maximum dose of 300 mg (150 mg for East Asian heritage) in order to maintain platelet counts at a safe and effective level (i.e. a level sufficient to avoid platelet transfusions and bleeding events). Subjects will receive azacitidine 75 mg/meter\^2 subcutaneously once daily for 7 days (+/- 3 day treatment window permitted) every 28 days, for at least 6 cycles if tolerated and until they are no longer receiving benefit (defined as at least stable disease per the investigator's assessment) or until disease progression, death, or unacceptable toxicity/adverse event. The subject may receive eltrombopag daily for the full 28 days each cycle for as long as the subject is receiving azacitidine
Drug: Eltrombopag · Drug: Azacitidine
Eligible subject will receive eltrombopag matching placebo. Subjects will receive azacitidine 75 mg/meter\^2 subcutaneously once daily for 7 days (+/- 3 day treatment window permitted) every 28 days, for at least 6 cycles if tolerated and until they are no longer receiving benefit (defined as at least stable disease per the investigator's assessment) or until disease progression, death, or unacceptable toxicity/adverse event. The subject may receive eltrombopag daily for the full 28 days each cycle for as long as the subject is receiving azacitidine
Drug: Azacitidine · Drug: Placebo
Eltrombopag will be round film-coated tablets containing eltrombopag equivalent to 50 mg (white to off-white), 200 mg and 300 mg (green) of eltrombopag free acid
Subcutaneous Injection (IV if local standard)
Eltrombopag matching placebo tablets
Eltrombopag matching placebo tablets will be supplied
Number of Participants Who Were Platelet Transfusion Independent During Cycles 1-4 of Azacitidine Therapy
A subject is defined as being platelet transfusion independent if they received no platelet transfusions within the first 4 cycles of treatment with azacitidine. Subjects who died or withdrew from investigational product within the first four cycles were treated as failures (i.e. not transfusion independent) in the analysis
Time frame: 4 cycles (Cycle = 28 days)
Overall Survival (OS)
Overall survival is defined as the time from randomization until death due to any cause and deaths have been presented. Subjects still alive at the time of the analysis and subjects who have withdrawn from the study will be censored at the time of last contact
Time frame: Randomization until death or end of study, approximately 2 years
Summary of Progression Free Survival From Investigator Assessment (ITT)
Progression-free survival, defined as the time from randomization until either disease progression or death. The modified 2006 IWG criteria for MDS used for progression assessment For patients with: Less than 5% BM blasts: ≥ 50% increase in blasts to \> 5% blasts; 5% - \<10% BM blasts: ≥ 50% increase to \> 10% blasts; 10% - \<20% BM blasts: ≥ 50% increase to \> 20% blasts; 20% - 30% BM blasts: ≥ 50% increase to \> 30% blasts
Time frame: First day of each cycle (Cycles 3+), at the end of therapy visit and every 3 months in follow-up for approximately 2 years
Summary of Progression Free Survival From Central Review (ITT)
Progression-free survival, defined as the time from randomization until either disease progression or death. The modified 2006 IWG criteria for MDS used for progression assessment For patients with: Less than 5% BM blasts: ≥ 50% increase in blasts to \> 5% blasts; 5% - \<10% BM blasts: ≥ 50% increase to \> 10% blasts; 10% - \<20% BM blasts: ≥ 50% increase to \> 20% blasts; 20% - 30% BM blasts: ≥ 50% increase to \> 30% blasts
Time frame: First day of each cycle (Cycles 3+), at the end of therapy visit and every 3 months in follow-up for approximately 2 years
Summary of AML Progression From Investigator Assessment and Central Review (ITT)
Progression to AML in MDS patients with baseline bone marrow blast \< 20% was defined as meeting definition of disease progression according to the modified 2006 IWG response criteria for MDS with the additional requirement that bone marrow blast or peripheral blast increases from \< 20% at baseline to ≥ 20% postbaseline. Progression assessment For patients with: Less than 5% BM blasts: ≥ 50% increase in blasts to \> 5% blasts; 5% - \<10% BM blasts: ≥ 50% increase to \> 10% blasts; 10% - \<20% BM blasts: ≥ 50% increase to \> 20% blasts; 20% - 30% BM blasts: ≥ 50% increase to \> 30% blasts
Time frame: First day of each cycle (Cycles 3+), at the end of therapy visit and every 3 months in follow-up for approximately 2 years
Best Disease Response From Investigator Assessment (ITT)
Best disease response is categorized as complete remission (CR), partial remission (PR), or marrow CR, stable disease, disease progression, or as non-evaluable; according to modified 2006 International Working Group (IWG) criteria for MDS
Time frame: At end of Cycle 6 (cycle=28 days) or end of therapy, whichever came first
Best Disease Response From Central Review (ITT)
Best disease response is categorized as complete remission (CR), partial remission (PR), or marrow CR, stable disease, disease progression, or as non-evaluable; according to modified 2006 International Working Group (IWG) criteria for MDS
Time frame: At end of Cycle 6 (cycle=28 days) or end of therapy, whichever came first
Hematologic Improvement (HI) in Platelets, Neutrophils, and Hemoglobin Based on the Modified IWG Criteria for MDS (ITT)
HI based on the modified IWG criteria for MDS. HI - Platelets (BL \<100Gi/L), response criteria= BL \<20: increase to\>20 and 100% at least for 56 days or BL \>=20: absolute increase of \>=30. HI - Neutrophils (BL \<1.0 Gi/L), response criteria=100% increase and an absolute increase \>0.5 Gi/L over BL for at least 56 days. HI-Hemoglobin (BL \<g/dL), response criteria=Hgb increase by \>=1.5 g/dL over BL, RBC transfusions(given for Hgb\<=9.0) reduced by \>=4 per 8w from BL
Time frame: From Day 1 to 4-week follow-up (samples collected weekly in Cycle 1, Days 1 and 15 in Cycles 2-6 and Day 1 of Cycles >=7)
Number of Participants Who Were Platelet Transfusion Independent (ITT Set)
Platelet transfusion independence is defined for each cycle as the number of participants who continue to the end of a cycle without requiring a platelet transfusion
Time frame: From Day 1 to end of study treatment up to approximately 2 years
Bleeding Adverse Events (AEs) >= Grade 3
Bleeding will be assessed by recording AEs or serious adverse events (SAEs) as graded according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4.0
Time frame: From Day 1 to 4-week follow-up up to approximately 2 years
Number of of Subjects With Azacitidine Dose Delays, Dose Reductions, Interruptions
The proportion of subjects with any delay, reduction or interruption in dosage of Azacitidine excluding those for non-medical reasons will be analyzed
Time frame: From Day 1 to 4-week follow-up up to approximately 2 years
Response Levels in All Domains of Euroquol-5 Dimensions of Health, 3 Response Levels (EQ-5D-3L™)
The EQ-5D is a general health status and health utility measure which captures 5 dimensions of health state: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. (EQ-5D is a trademark of the Stichting EuroQol Group) . C=cycle, D=Day
Time frame: From Day 1 to 4-week follow-up up to approximately 2 years
Functional Assessment of Chronic Disease Therapy-fatigue Subscale (FACIT-Fatigue) (ITT)
The FACIT-Fatigue subscale measures severity and impact of fatigue on functioning and Health Related QoL experienced in the past 7 days. Scale is a 13 item measure of fatigure. Items are scored on a 0-4 response scale ranging from "not at all" to "very much so". All items are summed to create a single fatigure score with a range from 0 to 52. Items are reverse scored when appropriate to provide a scale in which higher scores represent better functioning or less fatiigue (The FACIT Fatigue Scale is owned by David Cella, Ph.D.)
Time frame: From Day 1 to 4-week follow-up (Approximate median 9 Cycles+4 weeks follow-up) up to approximately 2 years
Medical Resource Utilization (MRU): Event -Hospitalizations Inpatient and Outpatient
MRU data will be collected for each subject. Events corresponding to unscheduled (not scheduled per protocol) hospitalizations
Time frame: From Day 1 to 4-week follow-up (Approximate median 9 Cycles+4 weeks follow-up) up to approximately 2 years
Medical Resource Utilization (MRU): Event and Use of Site Specific Medical Resources - Non-study Laboratory Tests
MRU data will be collected for each subject. Events corresponding to unscheduled (not scheduled per protocol) hospitalizations, office visits including consultations, laboratory and diagnostic tests (lab results, imaging etc.), and procedures prior to therapy initiation and during therapy will be collected
Time frame: From Day 1 to 4-week follow-up (Approximate median 9 Cycles+4 weeks follow-up) up to approximately 2 years
Medical Resource Utilization (MRU): Use of Site Specific Medical Resources
MRU data will be collected for each subject. Events corresponding to unscheduled (not scheduled per protocol) hospitalizations, office visits including consultations, laboratory and diagnostic tests (lab results, imaging etc.), and procedures prior to therapy initiation and during therapy will be collected
Time frame: From Day 1 to 4-week follow-up (Approximate median 9 Cycles+4 weeks follow-up) up to approximately 2 years
Summary of Post-Hoc Estimates of Steady-state Eltrombopag Cmax and Cmin Pharmacokinetic Parameters for a 50 mg Dose
Eltrombopag concentrations were analyzed using a population PK model along with data from other studies in healthy volunteers and in patients with MDS and/or AML. Post-hoc PK parameters were derived. Only patients from this study were included (163)
Time frame: Cycle 1, Week 2: Pre-dose, 1.5 and 3 hour post dose; Cycle 1, Week 3: 4, 5.5, and 7 hours post dose
Summary of Post-Hoc Estimates of Steady-state Eltrombopag AUC0 Infinity Pharmacokinetic Parameters for a 50 mg Dose
Eltrombopag concentrations were analyzed using a population PK model along with data from other studies in healthy volunteers and in patients with MDS and/or AML. Post-hoc PK parameters were derived. Only patients from this study were included (163)
Time frame: Cycle 1, Week 2: Pre-dose, 1.5 and 3 hour post dose; Cycle 1, Week 3: 4, 5.5, and 7 hours post dose
AUC0-infinity -Pharmacokinetic(s) Parameter of Azacitidine
An analysis of variance (ANOVA) on AUC0-infinity. The PK parameters were log transformed prior to analysis. The model included treatment as a fixed effect. Point estimates and their associated 90% CI were constructed for the differences in PK parameter values. The point estimates and their associated 90% CI were then back transformed to provide point estimates and 90% CI for the azacitidine + eltrombopag:azacitidine + placebo PK parameter ratios.
Time frame: Cycle 2 Day 1: Pre-dose, 15 min, 0.5, 1, 2 and 4 hr post dose
Cmax -Pharmacokinetic Parameter of Azacitidine
An analysis of variance (ANOVA) on Cmax . The PK parameters were log transformed prior to analysis. The model included treatment as a fixed effect. Point estimates and their associated 90% CI were constructed for the differences in PK parameter values. The point estimates and their associated 90% CI were then back transformed to provide point estimates and 90% CI for the azacitidine + ltrombopag:azacitidine + placebo PK parameter ratios.
Time frame: Cycle 2 Day 1: Pre-dose, 15 min, 0.5, 1, 2 and 4 hr post dose
| Milestone | Eltrombopag | Placebo |
|---|---|---|
| Started | 179 | 177 |
| Treated | 177 | 177 |
| Untreated | 2 | 0 |
| Completed | 0 | 0 |
| Not completed | 179 | 177 |
| Withdrew: Study closed/ terminated | 57 | 77 |
| Withdrew: Azacitidine tx discontinued | 53 | 46 |
| Withdrew: Adverse event | 39 | 24 |
| Withdrew: Withdrawal by subject | 15 | 16 |
| Withdrew: Physician decision | 15 | 13 |
| Withdrew: Lost to follow-up | 0 | 1 |
A subject is defined as being platelet transfusion independent if they received no platelet transfusions within the first 4 cycles of treatment with azacitidine. Subjects who died or withdrew from investigational product within the first four cycles were treated as failures (i.e. not transfusion independent) in the analysis
| Participants | Eltrombopag | Placebo |
|---|---|---|
| Yes - platelet transfusion independent | 28 | 55 |
| No - platelet transfusion independent | 151 | 122 |
Overall survival is defined as the time from randomization until death due to any cause and deaths have been presented. Subjects still alive at the time of the analysis and subjects who have withdrawn from the study will be censored at the time of last contact
| deaths (events) | Eltrombopag | Placebo |
|---|---|---|
| Overall Survival (OS) | 57 | 51 |
Progression-free survival, defined as the time from randomization until either disease progression or death. The modified 2006 IWG criteria for MDS used for progression assessment For patients with: Less than 5% BM blasts: ≥ 50% increase in blasts to \> 5% blasts; 5% - \<10% BM blasts: ≥ 50% increase to \> 10% blasts; 10% - \<20% BM blasts: ≥ 50% increase to \> 20% blasts; 20% - 30% BM blasts: ≥ 50% increase to \> 30% blasts
| participants | Eltrombopag | Placebo |
|---|---|---|
| Death | 34 | 36 |
| Disease progression | 38 | 30 |
Progression-free survival, defined as the time from randomization until either disease progression or death. The modified 2006 IWG criteria for MDS used for progression assessment For patients with: Less than 5% BM blasts: ≥ 50% increase in blasts to \> 5% blasts; 5% - \<10% BM blasts: ≥ 50% increase to \> 10% blasts; 10% - \<20% BM blasts: ≥ 50% increase to \> 20% blasts; 20% - 30% BM blasts: ≥ 50% increase to \> 30% blasts
| participants | Eltrombopag | Placebo |
|---|---|---|
| Death | 44 | 41 |
| Disease progression | 32 | 26 |
Progression to AML in MDS patients with baseline bone marrow blast \< 20% was defined as meeting definition of disease progression according to the modified 2006 IWG response criteria for MDS with the additional requirement that bone marrow blast or peripheral blast increases from \< 20% at baseline to ≥ 20% postbaseline. Progression assessment For patients with: Less than 5% BM blasts: ≥ 50% increase in blasts to \> 5% blasts; 5% - \<10% BM blasts: ≥ 50% increase to \> 10% blasts; 10% - \<20% BM blasts: ≥ 50% increase to \> 20% blasts; 20% - 30% BM blasts: ≥ 50% increase to \> 30% blasts
| participants | Eltrombopag | Placebo |
|---|---|---|
| Participants progressed-AML - investigator assess | 27 | 16 |
| Participants progressed to AML - Central Review | 21 | 10 |
Best disease response is categorized as complete remission (CR), partial remission (PR), or marrow CR, stable disease, disease progression, or as non-evaluable; according to modified 2006 International Working Group (IWG) criteria for MDS
| participant | Eltrombopag | Placebo |
|---|---|---|
| Complete response - CR | 15 | 26 |
| Marrow complete response | 8 | 14 |
| Partial response - PR | 13 | 22 |
| Stable disease | 50 | 47 |
| Progressive disease | 22 | 8 |
| Not evaluable | 32 | 33 |
| Overall Response (CR+Marrow+PR | 36 | 62 |
Best disease response is categorized as complete remission (CR), partial remission (PR), or marrow CR, stable disease, disease progression, or as non-evaluable; according to modified 2006 International Working Group (IWG) criteria for MDS
| participant | Eltrombopag | Placebo |
|---|---|---|
| Complete response - CR | 11 | 7 |
| Marrow complete response | 2 | 5 |
| Partial response - PR | 2 | 7 |
| Stable disease | 23 | 31 |
| Progressive disease | 24 | 17 |
| Not evaluable | 26 | 38 |
| Overall Response (CR+Marrow+PR) | 15 | 19 |
HI based on the modified IWG criteria for MDS. HI - Platelets (BL \<100Gi/L), response criteria= BL \<20: increase to\>20 and 100% at least for 56 days or BL \>=20: absolute increase of \>=30. HI - Neutrophils (BL \<1.0 Gi/L), response criteria=100% increase and an absolute increase \>0.5 Gi/L over BL for at least 56 days. HI-Hemoglobin (BL \<g/dL), response criteria=Hgb increase by \>=1.5 g/dL over BL, RBC transfusions(given for Hgb\<=9.0) reduced by \>=4 per 8w from BL
| participants | Eltrombopag | Placebo |
|---|---|---|
| Platelets | 56 | 57 |
| Neutrophils | 12 | 13 |
| Hemoglobin | 1 | 1 |
| Platelets and neutrophils | 10 | 11 |
| Platelets and hemoglobin | 1 | 1 |
| Neutrophils and hemoglobin | 1 | 1 |
| Platelets, neutrophils and hemoglobin | 1 | 1 |
Platelet transfusion independence is defined for each cycle as the number of participants who continue to the end of a cycle without requiring a platelet transfusion
| participants | Eltrombopag | Placebo |
|---|---|---|
| Screening (179,177) | 127 | 121 |
| Cycle 1 (175,173) | 68 | 87 |
| Cycle 2 (135,158) | 62 | 87 |
| Cycle 3 (105,131) | 68 | 94 |
| Cycle 4 (93,116) | 58 | 91 |
| Cycle 5 (76,108) | 49 | 76 |
| Cycle 6 (65,90) | 41 | 62 |
| Cycle 7 (47,74) | 29 | 50 |
| Cycle 8 (37,61) | 20 | 42 |
| Cycle 9 (28,46) | 19 | 36 |
| Cycle 10 (23,38) | 18 | 28 |
| Cycle 11 (19,29) | 13 | 20 |
| Cycle 12 (15,21) | 10 | 15 |
| Cycle 13 (12,16) | 7 | 10 |
| Cycle 14 (6,11) | 3 | 6 |
| Cycle 15 (3,5) | 2 | 3 |
| Cycle 16 (0,3) | 0 | 3 |
| Cycle 17 (0,3) | 0 | 0 |
Bleeding will be assessed by recording AEs or serious adverse events (SAEs) as graded according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4.0
| participant | Eltrombopag | Placebo |
|---|---|---|
| Any event - Grade 3 | 9 | 12 |
| Any event - Grade 4 | 2 | 2 |
| Any event - Grade 5 | 1 | 4 |
The proportion of subjects with any delay, reduction or interruption in dosage of Azacitidine excluding those for non-medical reasons will be analyzed
| participant | Eltrombopag | Placebo |
|---|---|---|
| Overall dose delay | 82 | 88 |
| Overall dose reduction | 7 | 16 |
| Overall dose interruption | 3 | 13 |
The EQ-5D is a general health status and health utility measure which captures 5 dimensions of health state: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. (EQ-5D is a trademark of the Stichting EuroQol Group) . C=cycle, D=Day
| participant | Eltrombopag | Placebo |
|---|---|---|
| Mobility C1, D1 (176, 173) L1- no problem walking | 94 | 105 |
| Mobility C1,D1 (176, 173) L2- some problem walking | 81 | 66 |
| Mobility C1, D1 (176,173) L3- confined to bed | 1 | 2 |
| Mobility Wk 4 FU (71,72) L1- no problem walking | 40 | 48 |
| Mobility Wk 4 FU (71,72) L2- some problem walking | 29 | 22 |
| Mobility Wk 4 FU (71,72) L3- confined to bed | 2 | 2 |
| Self-Care C1, D1 (176,173) L1-no problems | 140 | 125 |
| Self-Care C1, D1 (176,173) L2-some problems | 32 | 20 |
| Self-Care C1, D1 (176,173) L3-unable to | 4 | 51 |
| Self-Care Wk4 FU (71,72) L1-no problems | 56 | 62 |
| Self-Care Wk4 FU(71,72) L2-some problems | 13 | 9 |
| Self-Care Wk4 FU (71,72) L2-unable to wash/dress | 2 | 1 |
| Usual activities C1,D1(175,173) L1-no problem | 97 | 94 |
| Usual activities C1,D1(175,173) L2-some problem | 71 | 68 |
| Usual activities C1,D1(175,173) L3-unable to | 7 | 11 |
| Usual activities Wk4 FU (71,72) L1-no problem | 36 | 41 |
| Usual activities Wk4 FU (71,72) L1-some problem | 29 | 25 |
| Usual activities Wk4 FU (71,72) L3-unable to | 6 | 6 |
| Pain/discomfort C1,D1(176,173) L1-none | 97 | 89 |
| Pain/discomfort C1,D1(176,173) L2-moderate | 74 | 78 |
| Pain/discomfort C1,D1(176,173) L3-extreme | 5 | 6 |
| Pain/discomfort Wk4 FU (71,72) L1-none | 38 | 40 |
| Pain/discomfort Wk4 FU (71,72) L2-moderate | 28 | 27 |
| Pain/discomfort Wk4 FU (71,72) L3-extreme | 5 | 5 |
| Anxiety/depression C1 D1(176,173) L1-none | 96 | 112 |
| Anxiety/depression C1 D1(176,173) L2-moderately | 74 | 56 |
| Anxiety/depression C1 D1(176,173) L3-extremely | 6 | 5 |
| Anxiety/depression Wk4 FU(71,72) L1-none | 44 | 45 |
| Anxiety/depression Wk4 FU(71,72) L2-moderately | 24 | 25 |
| Anxiety/depression Wk4 FU(71,72) L3-extremely | 3 | 2 |
The FACIT-Fatigue subscale measures severity and impact of fatigue on functioning and Health Related QoL experienced in the past 7 days. Scale is a 13 item measure of fatigure. Items are scored on a 0-4 response scale ranging from "not at all" to "very much so". All items are summed to create a single fatigure score with a range from 0 to 52. Items are reverse scored when appropriate to provide a scale in which higher scores represent better functioning or less fatiigue (The FACIT Fatigue Scale is owned by David Cella, Ph.D.)
| scores | Eltrombopag | Placebo |
|---|---|---|
| Cycle 1 Day 1 (175,172) | 17.401 ± 11.0279 | 15.951 ± 10.9911 |
| Week 4 Follow-up (68,70) | 16.669 ± 10.7266 | 14.898 ± 12.2362 |
MRU data will be collected for each subject. Events corresponding to unscheduled (not scheduled per protocol) hospitalizations
| days | Eltrombopag | Placebo |
|---|---|---|
| In-patient hospitalizations - entire study (91,66) | 23.9 ± 24.33 | 27.1 ± 33.81 |
| Out-patient hospitalizations - entire study (4,2) | 9.5 ± 16.34 | 2.5 ± 0.71 |
MRU data will be collected for each subject. Events corresponding to unscheduled (not scheduled per protocol) hospitalizations, office visits including consultations, laboratory and diagnostic tests (lab results, imaging etc.), and procedures prior to therapy initiation and during therapy will be collected
| tests | Eltrombopag | Placebo |
|---|---|---|
| Medical Resource Utilization (MRU): Event and Use of Site Specific Medical Resources - Non-study Laboratory Tests | 88 | 105 |
MRU data will be collected for each subject. Events corresponding to unscheduled (not scheduled per protocol) hospitalizations, office visits including consultations, laboratory and diagnostic tests (lab results, imaging etc.), and procedures prior to therapy initiation and during therapy will be collected
| visits | Eltrombopag | Placebo |
|---|---|---|
| Medical or surgical specialist visits | 49 | 58 |
| Home healthcare visits by medical professional | 89 | 97 |
| Primary physician care visits | 89 | 97 |
| Nurse practitioner, physic assistant, nurse visits | 89 | 97 |
| Telephone consultations | 89 | 97 |
| Emergency visits not resulting in hospital stay | 89 | 97 |
Eltrombopag concentrations were analyzed using a population PK model along with data from other studies in healthy volunteers and in patients with MDS and/or AML. Post-hoc PK parameters were derived. Only patients from this study were included (163)
| μg/mL | Eltrombopag |
|---|---|
| Cmax | 7.70 ± 36.8 |
| Cmin | 4.41 ± 49.9 |
Eltrombopag concentrations were analyzed using a population PK model along with data from other studies in healthy volunteers and in patients with MDS and/or AML. Post-hoc PK parameters were derived. Only patients from this study were included (163)
| hr.μg/mL | Eltrombopag |
|---|---|
| Summary of Post-Hoc Estimates of Steady-state Eltrombopag AUC0 Infinity Pharmacokinetic Parameters for a 50 mg Dose | 135 ± 43.1 |
An analysis of variance (ANOVA) on AUC0-infinity. The PK parameters were log transformed prior to analysis. The model included treatment as a fixed effect. Point estimates and their associated 90% CI were constructed for the differences in PK parameter values. The point estimates and their associated 90% CI were then back transformed to provide point estimates and 90% CI for the azacitidine + eltrombopag:azacitidine + placebo PK parameter ratios.
| hr.ng/mL | Eltrombopag | Placebo |
|---|---|---|
| AUC0-infinity -Pharmacokinetic(s) Parameter of Azacitidine | 840 ± 53 | 641 ± 67 |
An analysis of variance (ANOVA) on Cmax . The PK parameters were log transformed prior to analysis. The model included treatment as a fixed effect. Point estimates and their associated 90% CI were constructed for the differences in PK parameter values. The point estimates and their associated 90% CI were then back transformed to provide point estimates and 90% CI for the azacitidine + ltrombopag:azacitidine + placebo PK parameter ratios.
| ng/mL | Eltrombopag | Placebo |
|---|---|---|
| Cmax -Pharmacokinetic Parameter of Azacitidine | 744 ± 91 | 535 ± 89 |
Collected over Timeframe for AE. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Eltrombopag | — | 128/177 (72.3%) | 159/177 (89.8%) |
| Placebo | — | 100/177 (56.5%) | 153/177 (86.4%) |
| Event | Eltrombopag | Placebo |
|---|---|---|
| Febrile neutropeniaBlood and lymphatic system disorders | 47/177 | 33/177 |
| PyrexiaGeneral disorders | 20/177 | 8/177 |
| PneumoniaInfections and infestations | 20/177 | 17/177 |
| SepsisInfections and infestations | 10/177 | 7/177 |
| Septic shockInfections and infestations | 10/177 | 5/177 |
| AnaemiaBlood and lymphatic system disorders | 5/177 | 7/177 |
| Acute kidney injuryRenal and urinary disorders | 7/177 | 2/177 |
| CellulitisInfections and infestations | 6/177 | 2/177 |
| Gastrointestinal haemorrhageGastrointestinal disorders | 1/177 | 5/177 |
| Urinary tract infectionInfections and infestations | 4/177 | 5/177 |
| Event | Eltrombopag | Placebo |
|---|---|---|
| ConstipationGastrointestinal disorders | 48/177 | 57/177 |
| NauseaGastrointestinal disorders | 54/177 | 46/177 |
| NeutropeniaBlood and lymphatic system disorders | 52/177 | 44/177 |
| PyrexiaGeneral disorders | 44/177 | 40/177 |
| DiarrhoeaGastrointestinal disorders | 42/177 | 25/177 |
| AstheniaGeneral disorders | 28/177 | 34/177 |
| VomitingGastrointestinal disorders | 33/177 | 29/177 |
| AnaemiaBlood and lymphatic system disorders | 32/177 | 19/177 |
| FatigueGeneral disorders | 31/177 | 27/177 |
| CoughRespiratory, thoracic and mediastinal disorders | 23/177 | 29/177 |
| Age, Continuous(years) | Eltrombopag | Placebo | Total |
|---|---|---|---|
| Mean | 68.3 ± 12.82 | 69.4 ± 10.58 | 68.8 ± 11.76 |
| Sex: Female, Male(Participants) | Eltrombopag | Placebo | Total |
|---|---|---|---|
| Female | 69 | 53 | 122 |
| Male | 110 | 124 | 234 |
| Race/Ethnicity, Customized(participants) | Eltrombopag | Placebo | Total |
|---|---|---|---|
| White | 146 | 148 | 294 |
| East Asian/Japanese/S.E. Asian | 26 | 23 | 49 |
| Central/South Asian | 0 | 2 | 2 |
| Other | 4 | 4 | 8 |
| Missing | 3 | 0 | 3 |
| IPSS risk score(participants) | Eltrombopag | Placebo | Total |
|---|---|---|---|
| Int - 1 (0.5-1.0) | 64 | 61 | 125 |
| Int - 2 (1.5 - 2.0) | 77 | 83 | 160 |
| High Risk (≥ 2.5) | 38 | 33 | 71 |
| Platelet Count(participants) | Eltrombopag | Placebo | Total |
|---|---|---|---|
| < 10 | 10 | 10 | 20 |
| ≥ 10 - <20 | 35 | 30 | 65 |
| ≥ 20 - <50 | 83 | 84 | 167 |
| ≥ 50 - <100 | 49 | 53 | 102 |
| ≥ 100 | 0 | 0 | 0 |
| missing | 2 | 0 | 2 |
| Platelet transfusion dependence(participants) | Eltrombopag | Placebo | Total |
|---|---|---|---|
| Yes | 29 | 37 | 66 |
| No | 150 | 140 | 290 |
Showing the first 100 of 158 sites across 30 countries. Choose a country and city above to see the rest.
Ran from Jun 2014 to primary completion in Apr 2016, 22 months.
Results were first posted in Dec 2017, 1 year 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Sep 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Eltrombopag